Hoboken, NJ, Rostock/Berlin, Germany, Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare as well as frequent disorders such as cancer or heart diseases at the earliest stage in order to start preventive and personalized treatment. One year after Arcensus was founded, fresh capital is now being raised for further expansion. As part of the current investment-series the Mittelstandische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV) are investing a single-digit million to further expand into the US and GCC regions. For MBMV, it is a very special investment, as Managing Director Dr. Thomas Drews reveals: “With Arcensus, we are
The post MBMV invests in international bio-tech startup Arcensus GmbH appeared first on Pharma Mirror Magazine.
